| Name | Title | Contact Details |
|---|
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.
OM1 is a leading health outcomes and registries company focused on the measurement, comparison, and prediction of treatment outcomes. Leveraging big data, standardized outcomes measurement, and artificial intelligence technology, OM1 built the first intelligent data cloud for healthcare, enabling more precise information and better decision making for stakeholders across the healthcare ecosystem.
DuvaSawko is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Daytona Beach, FL. To find more information about DuvaSawko, please visit www.duvasawko.com
LabRoots, Inc. is a Yorba Linda, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
A premier senior housing company through ownership and third party management that focuses on maximizing revenue drivers and operational efficiencies by allowing individual resident needs and preferences to drive service offerings and by focusing on resident and employee satisfaction.